

The impact of natural compounds on s-shaped a42 fibril: From molecular docking to biophysical characterization

Original

The impact of natural compounds on s-shaped a42 fibril: From molecular docking to biophysical characterization / Muscat, S.; Pallante, L.; Stojceski, F.; Danani, A.; Grasso, G.; Deriu, M. A.. - In: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. - ISSN 1661-6596. - 21:6(2020), p. 2017. [10.3390/ijms21062017]

Availability:

This version is available at: 11583/2877462 since: 2021-03-26T20:16:21Z

Publisher:

MDPI AG

Published

DOI:10.3390/ijms21062017

Terms of use:

This article is made available under terms and conditions as specified in the corresponding bibliographic description in the repository

Publisher copyright

(Article begins on next page)



Article

The Impact of Natural Compounds on S-Shaped A β ₄₂ Fibril: From Molecular Docking to Biophysical Characterization

Stefano Muscat ^{1,†}, Lorenzo Pallante ^{2,†}, Filip Stojceski ¹, Andrea Danani ¹,
Gianvito Grasso ¹ and Marco Agostino Deriu ^{2,*}

¹ Dalle Molle Institute for Artificial Intelligence (IDSIA), University of Italian Switzerland (USI), University of Applied Science and Art of Southern Switzerland (SUPSI), CH-6928 Manno, Switzerland; stefano.muscat@idsia.ch (S.M.); filip.stojceski@idsia.ch (F.S.); andrea.danani@idsia.ch (A.D.); gianvito.grasso@idsia.ch (G.G.)

² PolitoBIOMed Lab, Department of Mechanical and Aerospace Engineering, Politecnico di Torino, IT-10128 Torino, Italy; lorenzo.pallante@polito.it

* Correspondence: marco.deriu@polito.it

† Stefano Muscat and Lorenzo Pallante contributed equally to this study.

Received: 3 February 2020; Accepted: 13 March 2020; Published: 16 March 2020



Abstract: The pursuit for effective strategies inhibiting the amyloidogenic process in neurodegenerative disorders, such as Alzheimer's disease (AD), remains one of the main unsolved issues, and only a few drugs have demonstrated to delay the degeneration of the cognitive system. Moreover, most therapies induce severe side effects and are not effective at all stages of the illness. The need to find novel and reliable drugs appears therefore of primary importance. In this context, natural compounds have shown interesting beneficial effects on the onset and progression of neurodegenerative diseases, exhibiting a great inhibitory activity on the formation of amyloid aggregates and proving to be effective in many preclinical and clinical studies. However, their inhibitory mechanism is still unclear. In this work, ensemble docking and molecular dynamics simulations on S-shaped A β ₄₂ fibrils have been carried out to evaluate the influence of several natural compounds on amyloid conformational behaviour. A deep understanding of the interaction mechanisms between natural compounds and A β aggregates may play a key role to pave the way for design, discovery and optimization strategies toward an efficient destabilization of toxic amyloid assemblies.

Keywords: Alzheimer's disease; Amyloid β ; natural compounds; molecular dynamics; ensemble docking; S-shape

1. Introduction

Alzheimer disease (AD) is one of the most common forms of dementia. The mechanism of Alzheimer's onset and progression is still unclear, and several hypotheses have been proposed. One of the most accredited theories is the amyloid cascade hypothesis [1], which identifies as the main cause of AD progression the misfolding and the extracellular aggregation of Amyloid- β (A β) peptides from the cleavage of amyloid precursor protein (APP), as well as the intracellular deposition of the misfolded tau protein in neurofibrillary tangles. The A β aggregation leads to the formation of oligomeric toxic species, which can further aggregate in more ordered structures, called fibrils or fibres [2], up to the formation of extracellular senile plaques [3,4]. Among different lengths of A β peptides, senile aggregates are mostly made by the A β ₄₀ fibrils, but the most toxic species are the A β ₄₂ ones, due to their intrinsic tendency to self-assembly [5]. The stability of these structures is strongly linked with

the progression and severity of the disease, and in the last years, many efforts have been made to characterize the molecular stability of amyloid aggregates [6–14].

In the past, several strategies have been developed to reduce or prevent A β production and to destabilize A β aggregates, including immunotherapeutic vaccines [15,16], antibodies [17,18], peptides [19,20], nanoparticles [21–23] and compounds targeting A β secretases [24,25] and A β aggregation [26–31]. However, some of these approaches have shown serious side effects [32,33] and poor permeability through the blood-brain barrier (BBB) [34]. In this context, small molecules based on natural compounds are promising inhibitors with minimal side effects and increased BBB permeability [35]. Several *in vitro* and *in vivo* studies have highlighted the potential therapeutic effects of natural compounds against neurodegenerative diseases, including AD [36–42]. However, their effects affect several aspects associated with AD, and their molecular mechanism of action is still not clear, consequently reducing the percentage of compounds at the clinical trial stage [3]. Hence, a deep characterization of the molecular structure of amyloid aggregates and their interactions with promising compounds, such as natural ones, is of primary importance for the design of new efficient strategies against neurodegenerative diseases [43].

In this regard, computational methods, such as molecular dynamics (MD) simulations, thanks to a detailed molecular resolution, could represent a powerful tool to shed light on the molecular mechanisms characterizing physiological and pathological phenomena [44]. Thanks to these methods, several small molecules have been proposed as amyloid antiaggregating agents [45]. A promising inhibitor, referred to as wgx-50, has shown destabilizing effects against A β fibrils and inhibition of neural apoptosis and apoptotic gene expression [46–48]. Moreover, polyproline chains have demonstrated a conversion mechanism of the A β secondary structure from beta-sheet to random coil, highlighting the stabilizing role of amyloid C-terminal residues [49]. Sharma et al. have evaluated the stoichiometric ratio of caffeine to the A β -derived switch-peptide by a combination of experimental and computational approaches, observing the peptide disaggregation when the caffeine stoichiometric is ten times higher than the peptide one [50]. Furthermore, curcumin-like compounds have been synthesized and tested on A β_{40} showing two binding sites, one in the 17–21 region and one near the Met35 [51], which have been previously observed by experimental and computational works [52,53]. Finally, the interactions between homotaurine, scyllo-inositol and the A β_{42} peptide at the monomer level have been extensively investigated by very long replica exchange MD with solute tempering simulations of 160 μ s for each system, showing conformational changes of the A β_{42} monomer through a nonspecific binding mechanism [31].

In this context, it is worth mentioning that molecular modelling investigations have focused mostly on a specific A β_{42} polymorphic structure, called U-shaped fibril [54]. However, the A β_{42} may arrange also in other polymorphic structures, such as the S-shaped structural rearrangement [55]. Interestingly, recent works have indicated that the S-shaped structure is characterized by superior conformational and mechanical stability with respect to the U-shaped one, suggesting a correlation between structural stability and toxicity [11,12,56].

Based on the above-mentioned premises, this research work investigates the binding and action mechanisms of 57 natural compounds targeting the S-shape A β_{42} fibril by ensemble docking and molecular dynamics (MD) simulations. Ligands were selected starting from previous literature, and in particular *in vivo* or *in vitro* data showing their effect on the onset and progression of several neurological diseases, including AD [3,37–40]. Our results revealed the ligand's specific mechanisms of action on amyloid aggregates. More in detail, ligands can be distinguished based on their ability to disrupt or preserve the ordered conformational structure of the amyloid fibril.

2. Results

We first performed long MD simulations of the compound-free A β_{42} pentamer in order to obtain a representative structure for the docking protocol. The conformational stability of the three independent replicas of A β_{42} was demonstrated by the RMSD in the Supporting Information (Figure S1).

The MM–GBSA binding energy estimation of the 57 ligand–receptor complexes was computed during 1 ns of MD simulation, as previously done in the literature [57], and the results are reported in the Supporting Information (Table S1). The best ten compounds, characterized by the lowest values of binding energy, were selected (Figure 1) and further characterized by long MD simulations of 150 ns. Docking poses of the best compounds and their interaction maps are reported in the Supporting Information (Figures S3 and S4). See the Materials and Methods section for further details.




Figure 1. The ten best natural compounds that exhibited the lowest MM–GBSA binding energies for the selected S-shape amyloid fibril.

The MD simulations have pointed out three different mechanisms of action on the structural stability of the amyloid fibril. More in detail, (I) 6-shogaol and oleuropein were able to dock between adjacent receptor chains, inducing a considerable destabilizing effect on the whole protein; (II) curcumin, gossypin and piceatannol disrupted the ordered structure of the amyloid fibril after binding into a pocket formed by the protein S-shape; and (III) the remaining compounds, i.e., salvianolic acid A, beta-carotene, piperine, rosmarinic acid and withanolide A, did not result in remarkable protein conformational changes, thus suggesting a binding pocket stabilization. Representative snapshots of the three different mechanisms of action are reported in Figure 2.

In order to quantify the effects of the investigated compounds on the structural order of amyloid aggregates, three parameters were calculated on the last 25 ns of the MD simulations: (1) the beta-sheet structure probability; (2) the order parameter, calculated as described in Materials and Methods; and (3) the inter-chain interaction area, which measured the average contact surface between adjacent protein chains with a distance cut-off of 0.35 nm. All the above-mentioned analyses have been computed for the wild type protein, i.e., the ligand-free structure, and for all ligand–receptor complexes (Figure 3).

In Figure 3A, the beta-sheet probability is shown. The A β ₄₂ wild type was characterized by a beta structure percentage of 37.9% \pm 3.6% and each compound exhibited different effects on the protein conformational stability. Among the investigated compounds, only oleuropein, gossypin, piceatannol, curcumin and 6-shogaol proved to remarkably reduce the amyloid beta structure content. Similar trends were obtained for both the geometric order parameter and the inter-chain interaction area (Figure 3B,C). Therefore, oleuropein, gossypin, piceatannol, curcumin and 6-shogaol showed destabilizing effects by inducing a reduction in terms of (i) the protein beta sheet structure content, (ii) the fibril order (quantified by the estimated order parameter) and (iii) the inter-chain interaction

surface. On the above-mentioned three indicators, all the other investigated compounds demonstrated a negligible impact on the amyloid structure.




Figure 2. Representative snapshots of the three different mechanisms of action of selected natural compounds: interchain destabilization, pocket distortion and pocket stabilization. For each mechanism the (A) starting configurations after the docking protocol and the (B) final structures after 150 ns of molecular dynamics (MD) simulation are shown. The ligands are represented in red, while the amyloid fibrils and their residues within 0.35 nm from the ligand are represented in grey and yellow, respectively.

From the visual inspection of the ligand–receptor binding mechanisms, it was evident that different compounds interacted with different areas of the protein, making contact with distinct residues. Hence, to better quantify these differences, the ligand–receptor contact probability was evaluated. For each MD trajectory frame, the distance between all A β ₄₂ residues and the considered compound was calculated, and the contact was counted if this distance was below a cut-off of 0.35 nm. The contact probability was then defined as the total number of contacts divided by the total number of simulation frames. The contact probability between each ligand and protein residue is reported in Figure 4. It should be noted that we have not distinguished between the same residues of different protein chains, and therefore the obtained heatmap underlines the probability of interaction of a specific residue with the considered compound. This method was chosen since the original structure of the fibrillar aggregate is formed by the repetition of identical laterally bound chains. Therefore, the only noteworthy information is the residue type involved in the interaction and not the chain that it belongs to. Furthermore, it is worth noticing that 6-shogaol detached from its binding site during the simulation. Therefore, its contact probability was estimated only for the frames in which the compound was effectively docked into the binding site. In detail, the contact probability map identified two main binding areas: residues E11–F19 and residues I32–L34. Residues mainly involved in the binding process are mostly non-polar (50%) and basic (25%), suggesting that these properties are of primary importance for an effective ligand binding. Moreover, it is important to mention that 6-shogaol and oleuropein interacted less with

the above-mentioned residues, since they were docked between adjacent protein chains. In particular, 6-shogaol was shown to mostly interact with the H14–G25 region, whereas oleuropein was found mainly bound to the V18–V24 and N27–I31 ones. The other compounds, instead, were buried into the binding pocket identified by the amyloid fibril S-shape and interacted with similar residues. However, rosmarinic acid expressed a slightly different behaviour, mostly interacting with the chain edge and showing a tendency to not penetrate into the binding pocket.




Figure 3. (A) Beta-sheet structure probability, (B) order parameter and (C) inter-chain interaction area for the wild type amyloid fibrils and all the receptor–ligand complexes.




Figure 4. Contact probability between the selected natural compounds and the amyloid residues during the MD simulations.

In order to better characterize ligand properties, which are at the basis of their mechanisms, pharmacophore modelling was performed using LigandScout software [58]. This method allowed

the definition of shared features among the properties of a series of compounds. More in detail, Figure 5A represents the common features between 6-shogaol and oleuropein, which were able to dock between adjacent chains (mechanism I). Otherwise, Figure 5B shows the common features between the ligands that led to the pocket distortion (mechanism II). All destabilizing compounds share six common features, i.e., three H bond acceptors (HBA), one H bond donor (HBD), one aromatic ring (AR) and one hydrophobic interaction (H). It is worth mentioning that the first shared features model was characterized by one more hydrophobic feature than the second one. Hence, this property can probably be related to the ability of 6-shogaol and oleuropein to interpose between protein chains. Moreover, adding any one of the compounds that exhibited lower or no destabilizing effects (mechanism III), the shared pharmacophore model lost at least one “H bond acceptor” feature. For this reason, this characteristic seems crucial in the definition of the ligand destabilizing activity on the protein conformation.




Figure 5. Pharmacophore model based on shared features between (A) 6-shogaol and oleuropein and (B) curcumin, gossypin and piceatannol. HBA identifies a hydrogen bond acceptor, HBD a hydrogen bond donor, AR an aromatic ring and H a hydrophobic interaction.

3. Discussion

Among several neurological disorders, AD is one of the most common forms of dementia. Even though the causes of the Alzheimer’s onset and progression are still under debate, according to the amyloid cascade hypothesis [1], the amyloidogenic process that leads to the formation of extracellular aggregates of A β peptides is considered one of the main markers of Alzheimer’s occurrence and severity. Until now, only two strategies are used to provide symptomatic relief to AD patients: acetylcholinesterase inhibitors, to maintain the level of acetylcholine in the brain, and

N-methyl-D-aspartate receptor antagonists, to prevent excitotoxicity [59]. Unfortunately, serious side effects and poor effectiveness in some phases of the disease have been detected [40,60,61]. Between different lengths of ordered and disordered amyloid peptides, the A β ₄₂ fibril is known to be the most toxic due to its tendency to self-assembly into ordered structures [5]. Moreover, this structure presents two different structural rearrangements, S-shaped and the U-shaped [54,55]. In the last years, several studies have investigated the different behaviour of these polymorphisms and the S-shaped form has demonstrated greater conformational and mechanical stability than the U-shaped form [11,12,56]. Therefore, the S-shaped structure represents the primary target for pharmacological treatments, aimed to reduce the amyloidogenic process and interfere with the amyloid aggregates' stability. In this context, the search for destabilizers of A β fibrils may provide fruitful insights in the open research for treatments targeting AD. Natural compounds have shown promising effects, proving to be effective in many *in vitro* and *in vivo* studies with minimal side effects and increased blood brain barrier permeability [35]. However, the molecular mechanism of action of these compounds is still unclear and several computational studies have tried to characterize their effects on different amyloid aggregates [31,43,45–47,49–53]. In this work, a combination of ensemble docking and MD simulations has been applied to evaluate the influence of 57 promising compounds on preformed S-shape A β ₄₂ fibrils [3,37–40]. We identify three different mechanisms of action for the best ten natural compounds: (I) inter-chain destabilization, (II) pocket distortion and (III) pocket stabilization. In particular, 6-shogaol and oleuropein (mechanism I) are able to disrupt the protein ordered structure docking between adjacent fibril chains; curcumin, gossypin and piceatannol (mechanism II) dock into a binding pocket identified by the amyloid S-shape, affecting the whole protein conformation; the other ligands (mechanism III), instead, preserve or slightly influence the conformational state of the amyloid fibril. In this way, we find out that only 6-shogaol, oleuropein, curcumin, gossypin and piceatannol appreciably affect the protein stability, reducing the percentual content of beta sheets, the order parameter value and the inter-chain interaction area if compared to the wild type structure. It is worth remarking that the ligands belonging to mechanisms I and II have demonstrated similar conformational effects on the amyloid fibril, inducing similar reductions of beta-sheet structure content, order parameter and inter-chain interaction area. Therefore, all the identified destabilizing compounds, i.e., 6-shogaol, curcumin, gossypin, oleuropein and piceatannol, are underlined for further investigations. Moreover, compound shared features may be used for determining a pharmacophore model to rationally design novel compounds, hopefully characterized by a more effective destabilizing strength on A β toxic assemblies. To remark on the importance of the selected compounds' chemical features, it is worth mentioning that brazilin, a modulator of the amyloid fibril conformation [62], shares five common features with the here characterized destabilizing ligands belonging to classes I and II (Figure S5).

The remaining compounds seem to stabilize the binding pocket, maintaining an ordered structure of the amyloid aggregate. Concerning previous literature [31,48,51,63], the present research expresses some aspects of novelty. In particular, this work considers the S-shaped polymorphism as the ligand target. Previous computational works have mostly studied a different amyloid polymorphism, namely the U-shaped one [47,48,51], which might be less stable than the S-shaped one [11,12]. Moreover, this work also provides a comprehensive comparative investigation on a considerable number of natural inhibitors, investigating their binding and action mechanisms.

Most of the selected compounds have shown antioxidant and anti-inflammatory properties *in vivo* [3,64–67]. Recent studies have remarked the destabilization action of curcumin on A β ₄₀ and A β ₄₂ [68], also with advanced amyloid accumulation [63,69]. Furthermore, it has been observed that oleuropein acts against the formation of toxic oligomer and amyloid fibrils, favouring the formation of non-toxic aggregates and improving cognitive functions [3,65,70–72]. It is worth mentioning that mechanism-III compounds have proven beneficial effects on AD onset and progression. Therefore, their mechanism of action probably alters the fibril structure in a different stage of the pathology

or mostly affects other important factors of the disease, including the oxidative stress, the tau hyperphosphorylation, the α -secretase expression and the β -secretase activity.

Most ligands, except for 6-shogaol and oleuropein, interact with common residues in two main binding areas, identified by residues E11–F19 and I32–L34. Therefore, these residues seem crucial for the definition of the binding pocket and for the effective binding of the investigated compounds. Similar regions have been identified by previous studies about curcumin-like compounds in a complex with the U-shape polymorphism [51,52]. Moreover, in vitro studies have shown the key role of F19 and F20 for efficient $A\beta_{42}$ polymerization [73]. Finally, the pharmacophore modelling highlights common features between the destabilizing compounds, outlining the presence of an additional hydrophobic characteristic for the mechanism-I compounds. This feature could probably be related to the ability of 6-shogaol and oleuropein to fit between protein chains. All ligands share aromatic characteristics that have been seen to be important for interacting with amyloidogenic aggregates [74]. Moreover, the presence of three H-bond acceptor features is common to all the destabilizing compounds, but not for the other ones, suggesting that this could be an important characteristic for an effective binding to the amyloid fibril and for the activity of the investigated chemicals.

As a limit of the present research, it is worth mentioning that molecular simulations employed in this work cannot represent the entire amyloidogenic process and the present study is focused on the action of natural compounds on preformed amyloid fibrils. Only experimental studies may access the proper time and length scales to correctly describe the whole fibrillogenic process. However, the present research represents a meaningful comparative investigation with atomic resolution, which helps the ligand screening workflow by elucidating binding and action mechanisms of a considerable number of existing natural compounds already considered in the AD research field. Future developments might consider combinations of different compounds, as well as the effect of different compound concentrations to better clarify potential cooperative or competitive mechanisms.

4. Materials and Methods

4.1. Molecular Dynamics Setup

The atomistic structure of the S-shape $A\beta_{42}$ fibril was obtained from solid-state NMR (PDB ID: 2MXU [54]). Only five of the twelve chains of $A\beta_{42}$ were extracted as previously done in the literature [11]. Water molecules were added to a periodic cubic box with sides of 8 nm. The total system charge was neutralized adding Na^+ and Cl^- ions at a concentration of 150 mM. The AMBER99-ILDN force-field [75] and TIP3P model [76] were employed to define protein and water molecule topologies, respectively. A time step of 2 fs was used together with the LINCS constraints algorithm [77]. All subsequent operations were performed three times obtaining three different replicas in order to increase the statistics of the MD data. The systems were minimized using the steepest descent method and then simulated with position restraints on protein heavy atoms for 200 ps in NVT ensemble using the V-rescale coupling method [78] to maintain a temperature of 300 K. We further simulated the system with the above-described position restraints in NPT ensemble for 400 ps using the V-rescale thermostat [78] and isotropic Berendsen barostat [79] to maintain temperature (300 K) and pressure (1 bar), respectively. Finally, MD simulations were performed without any restraints for 200 ns under NPT ensemble, using the V-rescale [78] and Parrinello-Rahman [80] coupling methods. The short-ranged Van der Waals (VDW) interactions were cut off after 1 nm and long-ranged electrostatic interactions were calculated using the Particle Mesh Ewald (PME) method [81]. All simulations were carried out by GROMACS 2018 software package [82], while the Visual Molecular Dynamics (VMD) package was employed for the visual inspection of the simulated systems [83].

4.2. Molecular Docking Protocol

For each of the above-mentioned replicas, a cluster analysis was performed during the last 50 ns using linkage method [82] and a RMSD cut-off of 0.1 nm, as done previously in the literature [84].

The centroid of the most populated cluster for each replica was assumed as the starting receptor configuration (see Figure S2).

Structures of the 57 investigated ligands were downloaded from the PubChem database [85] and their protonation state was computed using Molecular Operating Environment software (MOE). The complete list of chosen natural compounds with their physiological charge was reported in the Supporting Information (Table S1). Then, ligand topologies were obtained with Antechamber [86,87] using the General Amber Force Field (GAFF) [86] and AM1-BCC charge method [88], as applied in previous studies [48,89–92].

Molecular docking was carried out by AutoDock Vina [93] using 64 as exhaustiveness and a search box of 9 nm x 9 nm x 12 nm, located at the centre of the protein and able to cover the entire protein surface. Each ligand was docked to the three different centroid configurations and only the best mode in terms of Vina binding affinity was selected, obtaining 57 receptor–ligand complexes.

4.3. Binding Energy Estimation and Protein–Compounds Conformational Dynamics

Each receptor–ligand complex system was followed by solvation, neutralization, energy minimization, position-restrained MD and a short MD production of 1 ns, with the same setup described in the molecular dynamics setup section. Then, the receptor–ligand binding energy was estimated by the MM–GBSA method [94] using parameters from previous literature [57,95,96].

The ten best ligands in terms of binding energy were further characterized by a MD simulation of 150 ns, in order to highlight the conformational changes of the amyloid fibril induced by the presence of natural compounds. Finally, the three starting receptor configurations were simulated using the above-mentioned protocol for 150 ns in order to compare the structural effects in the absence of ligands. Three replicas for each system were performed to check the reliability of the results. A simulations summary is reported in the Supporting Information (Table S2).

4.4. Order Parameter

The A β ₄₂ fibrils were characterized by a regular shape, repeated in each chain. In order to estimate the structural order of the pentamer, an order parameter (ordP) was calculated similarly to previous works [11,13,14,97]:

$$\text{ordP} = \frac{\sum_{c=1}^{Nc} (\sum_{n=1}^{Nr} (\overrightarrow{\text{CoM}_0 - \text{C}\alpha_0}) \cdot (\overrightarrow{\text{CoM}_t - \text{C}\alpha_t}))}{Nr Nc} \quad (1)$$

Here, the arrow represents the connecting vector of the centre of mass (CoM) position and alpha carbon (C α) position of the n-th residue and of the c-th chain. The ordP is the dot product averaged along the observation time interval, the number of residues (NR) and the number of the chains (NC). Values of ordP close to 1 indicated an alignment close to the initial structure, i.e., aligned fibres along the fibril axis z. Values of ordP lower than 1 indicated a gradual structure distortion.

5. Conclusions

In this work, molecular modelling techniques were employed to screen among 57 natural compounds. Five ligands, i.e., 6-shogaol, oleuropein, curcumin, gossypin and piceatannol, showed a remarkable destabilizing activity on the A β ₄₂ S-shape polymorphism. Two different destabilizing modes of action of the inspected ligands were revealed. Finally, throughout pharmacophore modelling, the main common features of the highlighted ligands have been identified. These chemical features can be considered for further rational search/design of amyloid destabilizing agents. For greater detail, future studies may expand the database of the investigated compounds, including possible other interesting natural ligands characterized by shared chemical features with respect to those identified in this work. Moreover, further works may consider effects of ligand concentration, combinations of

destabilizing compounds or the presence of different species of metal ions involved in the ligand-target binding mechanism.

Supplementary Materials: Supplementary materials can be found at <http://www.mdpi.com/1422-0067/21/6/2017/s1>.

Author Contributions: Conceptualization, G.G. and M.A.D.; data curation, S.M., L.P., G.G. and M.A.D.; formal analysis, S.M., L.P., G.G. and M.A.D.; funding acquisition, M.A.D.; investigation, S.M. and L.P.; methodology, S.M., L.P., F.S., G.G. and M.A.D.; project administration, G.G. and M.A.D.; resources, M.A.D.; supervision, G.G. and M.A.D.; visualization, S.M., L.P. and G.G.; writing—original draft, S.M., L.P., F.S., A.D., G.G. and M.A.D.; writing—review and editing, S.M., L.P., F.S., A.D., G.G. and M.A.D. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Acknowledgments: This work was supported by a grant from the Swiss National Supercomputing Centre (CSCS). The research has been developed as part of the Virtuous project, funded by the European Union's Horizon 2020 research and innovation programme under the Maria Skłodowska-Curie—RISE Grant Agreement No 872181.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

AD	Alzheimer's Disease
BBB	Blood Brain Barrier
APP	Amyloid Precursor Protein
MM-GBSA	Molecular Mechanics-Generalized Born Surface Area
VDW	Van der Waals
PME	Particle Mesh Ewald
GAFF	General Amber Force Field
RMSD	Root Mean Square Deviations
ordP	Order Parameter

References

- Selkoe, D.J. The molecular pathology of Alzheimer's disease. *Neuron* **1991**, *6*, 487–498. [[CrossRef](#)]
- Cummings, J.L. Alzheimer's Disease. *N. Engl. J. Med.* **2004**, *351*, 56–67. [[CrossRef](#)] [[PubMed](#)]
- Andrade, S.; Ramalho, M.J.; Loureiro, J.A.; Do Carmo Pereira, M. Natural compounds for alzheimer's disease therapy: A systematic review of preclinical and clinical studies. *Int. J. Mol. Sci.* **2019**, *20*, 2313. [[CrossRef](#)]
- Selkoe, D.J.; Hardy, J. The amyloid hypothesis of Alzheimer's disease at 25 years. *EMBO Mol. Med.* **2016**, *8*, 595–608. [[CrossRef](#)] [[PubMed](#)]
- Cohen, S.I.A.; Linse, S.; Luheshi, L.M.; Hellstrand, E.; White, D.A.; Rajah, L.; Otzen, D.E.; Vendruscolo, M.; Dobson, C.M.; Knowles, T.P.J. Proliferation of amyloid-42 aggregates occurs through a secondary nucleation mechanism. *Proc. Natl. Acad. Sci. USA* **2013**, *110*, 9758–9763. [[CrossRef](#)] [[PubMed](#)]
- Schütz, A.K.; Vagt, T.; Huber, M.; Ovchinnikova, O.Y.; Cadalbert, R.; Wall, J.; Güntert, P.; Böckmann, A.; Glockshuber, R.; Meier, B.H. Atomic-Resolution Three-Dimensional Structure of Amyloid β Fibrils Bearing the Osaka Mutation. *Angew. Chemie Int. Ed.* **2015**, *54*, 331–335. [[CrossRef](#)]
- Guo, S.; Akhremitchev, B.B. Packing density and structural heterogeneity of insulin amyloid fibrils measured by AFM nanoindentation. *Biomacromolecules* **2006**, *7*, 1630–1636. [[CrossRef](#)]
- VandenAkker, C.C.; Engel, M.F.M.; Velikov, K.P.; Bonn, M.; Koenderink, G.H. Morphology and Persistence Length of Amyloid Fibrils Are Correlated to Peptide Molecular Structure. *J. Am. Chem. Soc.* **2011**, *133*, 18030–18033. [[CrossRef](#)]
- Palhano, F.L.; Lee, J.; Grimster, N.P.; Kelly, J.W. Toward the Molecular Mechanism(s) by Which EGCG Treatment Remodels Mature Amyloid Fibrils. *J. Am. Chem. Soc.* **2013**, *135*, 7503–7510. [[CrossRef](#)]
- Wang, T.; Jo, H.; DeGrado, W.F.; Hong, M. Water Distribution, Dynamics, and Interactions with Alzheimer's β -Amyloid Fibrils Investigated by Solid-State NMR. *J. Am. Chem. Soc.* **2017**, *139*, 6242–6252. [[CrossRef](#)]
- Grasso, G.; Rebella, M.; Muscat, S.; Morbiducci, U.; Tuszyński, J.; Danani, A.; Deriu, M. Conformational Dynamics and Stability of U-Shaped and S-Shaped Amyloid β Assemblies. *Int. J. Mol. Sci.* **2018**, *19*, 571. [[CrossRef](#)] [[PubMed](#)]

12. Grasso, G.; Rebella, M.; Morbiducci, U.; Tuszynski, J.A.; Danani, A.; Deriu, M.A. The Role of Structural Polymorphism in Driving the Mechanical Performance of the Alzheimer's Beta Amyloid Fibrils. *Front. Bioeng. Biotechnol.* **2019**, *7*, 83. [[CrossRef](#)] [[PubMed](#)]
13. Miceli, M.; Muscat, S.; Morbiducci, U.; Cavaglià, M.; Deriu, M.A. Ultrasonic waves effect on S-shaped β -amyloids conformational dynamics by non-equilibrium molecular dynamics. *J. Mol. Graph. Model.* **2020**, *96*, 107518. [[CrossRef](#)] [[PubMed](#)]
14. Muscat, S.; Stojceski, F.; Danani, A. Elucidating the Effect of Static Electric Field on Amyloid Beta 1–42 Supramolecular Assembly. *J. Mol. Graph. Model.* **2020**, *96*, 107535. [[CrossRef](#)]
15. Lambrecht-Washington, D.; Rosenberg, R.N. Advances in the development of vaccines for Alzheimer's disease. *Discov. Med.* **2013**, *15*, 319–326.
16. Wang, C.Y.; Wang, P.-N.; Chiu, M.-J.; Finstad, C.L.; Lin, F.; Lynn, S.; Tai, Y.-H.; De Fang, X.; Zhao, K.; Hung, C.-H.; et al. UB-311, a novel UBITH[®] amyloid β peptide vaccine for mild Alzheimer's disease. *Alzheimer's Dement. Transl. Res. Clin. Interv.* **2017**, *3*, 262–272. [[CrossRef](#)]
17. Gold, M. Phase II clinical trials of anti-amyloid β antibodies: When is enough, enough? *Alzheimer's Dement. Transl. Res. Clin. Interv.* **2017**, *3*, 402–409. [[CrossRef](#)]
18. van Dyck, C.H. Anti-Amyloid- β Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise. *Biol. Psychiatry* **2018**, *83*, 311–319. [[CrossRef](#)]
19. Rajasekhar, K.; Madhu, C.; Govindaraju, T. Natural Tripeptide-Based Inhibitor of Multifaceted Amyloid β Toxicity. *ACS Chem. Neurosci.* **2016**, *7*, 1300–1310. [[CrossRef](#)]
20. Viet, M.H.; Ngo, S.T.; Lam, N.S.; Li, M.S. Inhibition of Aggregation of Amyloid Peptides by Beta-Sheet Breaker Peptides and Their Binding Affinity. *J. Phys. Chem. B* **2011**, *115*, 7433–7446. [[CrossRef](#)]
21. Lin, D.; Qi, R.; Li, S.; He, R.; Li, P.; Wei, G.; Yang, X. Interaction Dynamics in Inhibiting the Aggregation of A β Peptides by SWCNTs: A Combined Experimental and Coarse-Grained Molecular Dynamic Simulation Study. *ACS Chem. Neurosci.* **2016**, *7*, 1232–1240. [[CrossRef](#)] [[PubMed](#)]
22. Liu, F.; Wang, W.; Sang, J.; Jia, L.; Lu, F. Hydroxylated Single-Walled Carbon Nanotubes Inhibit A β 42 Fibrillogenesis, Disaggregate Mature Fibrils, and Protect against A β 42-Induced Cytotoxicity. *ACS Chem. Neurosci.* **2019**, *10*, 588–598. [[CrossRef](#)] [[PubMed](#)]
23. Xiong, N.; Dong, X.Y.; Zheng, J.; Liu, F.F.; Sun, Y. Design of LVFFARK and LVFFARK-Functionalized Nanoparticles for Inhibiting Amyloid β -Protein Fibrillation and Cytotoxicity. *ACS Appl. Mater. Interfaces* **2015**, *7*, 5650–5662. [[CrossRef](#)] [[PubMed](#)]
24. MacLeod, R.; Hillert, E.-K.; Cameron, R.T.; Baillie, G.S. The role and therapeutic targeting of α -, β - and γ -secretase in Alzheimer's disease. *Futur. Sci. OA* **2015**, *1*, fso.15.9. [[CrossRef](#)]
25. Cui, J.; Wang, X.; Li, X.; Wang, X.; Zhang, C.; Li, W.; Zhang, Y.; Gu, H.; Xie, X.; Nan, F.; et al. Targeting the γ -/ β -secretase interaction reduces β -amyloid generation and ameliorates Alzheimer's disease-related pathogenesis. *Cell Discov.* **2015**, *1*, 15021. [[CrossRef](#)]
26. Nie, Q.; Du, X.G.; Geng, M.Y. Small molecule inhibitors of amyloid β peptide aggregation as a potential therapeutic strategy for Alzheimer's disease. *Acta Pharmacol. Sin.* **2011**, *32*, 545–551. [[CrossRef](#)]
27. Zhu, M.; De Simone, A.; Schenk, D.; Toth, G.; Dobson, C.M.; Vendruscolo, M. Identification of small-molecule binding pockets in the soluble monomeric form of the A β 42 peptide. *J. Chem. Phys.* **2013**, *139*. [[CrossRef](#)]
28. Doig, A.J.; Derreumaux, P. Inhibition of protein aggregation and amyloid formation by small molecules. *Curr. Opin. Struct. Biol.* **2015**, *30*, 50–56. [[CrossRef](#)]
29. Habchi, J.; Chia, S.; Limbocker, R.; Mannini, B.; Ahn, M.; Perni, M.; Hansson, O.; Arosio, P.; Kumita, J.R.; Challa, P.K.; et al. Systematic development of small molecules to inhibit specific microscopic steps of A β 42 aggregation in Alzheimer's disease. *Proc. Natl. Acad. Sci. USA* **2017**, *114*, E200–E208. [[CrossRef](#)]
30. Liu, F.; Ma, Z.; Sang, J.; Lu, F. Edaravone inhibits the conformational transition of amyloid- β 42: Insights from molecular dynamics simulations. *J. Biomol. Struct. Dyn.* **2019**, *1*–12. [[CrossRef](#)]
31. Liang, C.; Savinov, S.N.; Fejzo, J.; Eyles, S.J.; Chen, J. Modulation of Amyloid- β 42 Conformation by Small Molecules Through Nonspecific Binding. *J. Chem. Theory Comput.* **2019**, *15*, 5169–5174. [[CrossRef](#)] [[PubMed](#)]
32. Orgogozo, J.M.; Gilman, S.; Dartigues, J.F.; Laurent, B.; Puel, M.; Kirby, L.C.; Jouanny, P.; Dubois, B.; Eisner, L.; Flitman, S.; et al. Subacute meningoencephalitis in a subset of patients with AD after A β 42 immunization. *Neurology* **2003**, *61*, 46–54. [[CrossRef](#)] [[PubMed](#)]
33. Frid, P.; Anisimov, S.V.; Popovic, N. Congo red and protein aggregation in neurodegenerative diseases. *Brain Res. Rev.* **2007**, *53*, 135–160. [[CrossRef](#)] [[PubMed](#)]

34. Zenaro, E.; Piacentino, G.; Constantin, G. The blood-brain barrier in Alzheimer's disease. *Neurobiol. Dis.* **2017**, *107*, 41–56. [[CrossRef](#)] [[PubMed](#)]
35. Bui, T.T.; Nguyen, T.H. Natural product for the treatment of Alzheimer's disease. *J. Basic Clin. Physiol. Pharmacol.* **2017**, *28*, 413–423. [[CrossRef](#)] [[PubMed](#)]
36. Butler, M.S.; Robertson, A.A.B.; Cooper, M.A. Natural product and natural product derived drugs in clinical trials. *Nat. Prod. Rep.* **2014**, *31*, 1612–1661. [[CrossRef](#)]
37. Andrade, S.; Ramalho, M.J.; Loureiro, J.A.; Pereira, M.C. Interaction of natural compounds with biomembrane models: A biophysical approach for the Alzheimer's disease therapy. *Colloids Surfaces B Biointerfaces* **2019**, *180*, 83–92. [[CrossRef](#)]
38. Rasool, M.; Malik, A.; Qureshi, M.S.; Manan, A.; Pushparaj, P.N.; Asif, M.; Qazi, M.H.; Qazi, A.M.; Kamal, M.A.; Gan, S.H.; et al. Recent Updates in the Treatment of Neurodegenerative Disorders Using Natural Compounds. *Evidence-Based Complement. Altern. Med.* **2014**, *2014*, 1–7. [[CrossRef](#)]
39. Hiremathad, A. A Review: Natural Compounds as Anti-Alzheimer's Disease Agents. *Curr. Nutr. Food Sci.* **2017**, *13*. [[CrossRef](#)]
40. Deb, S.; Mazumder, M.K.; Dutta, A.; Phukan, B.C.; Bhattacharya, P.; Paul, R.; Borah, A. Therapeutic implications of anti-inflammatory natural products in Alzheimer's disease. In *Discovery and Development of Anti-Inflammatory Agents from Natural Products*; Elsevier: Amsterdam, The Netherlands, 2019; pp. 241–258. ISBN 9780128169926.
41. Mourtas, S.; Canovi, M.; Zona, C.; Aurilia, D.; Niarakis, A.; La Ferla, B.; Salmona, M.; Nicotra, F.; Gobbi, M.; Antimisiaris, S.G. Curcumin-decorated nanoliposomes with very high affinity for amyloid- β 1-42 peptide. *Biomaterials* **2011**, *32*, 1635–1645. [[CrossRef](#)]
42. Ringman, J.; Frautschy, S.; Cole, G.; Masterman, D.; Cummings, J. A Potential Role of the Curry Spice Curcumin in Alzheimers Disease. *Curr. Alzheimer Res.* **2005**, *2*, 131–136. [[CrossRef](#)] [[PubMed](#)]
43. Knowles, T.P.; Fitzpatrick, A.W.; Meehan, S.; Mott, H.R.; Vendruscolo, M.; Dobson, C.M.; Welland, M.E. Role of intermolecular forces in defining material properties of protein nanofibrils. *Science* **2007**, *318*, 1900–1903. [[CrossRef](#)] [[PubMed](#)]
44. Bidone, T.C.; Kim, T.; Deriu, M.A.; Morbiducci, U.; Kamm, R.D. Multiscale impact of nucleotides and cations on the conformational equilibrium, elasticity and rheology of actin filaments and crosslinked networks. *Biomech. Model. Mechanobiol.* **2015**, *14*, 1143–1155. [[CrossRef](#)] [[PubMed](#)]
45. Fan, H.-M.; Xu, Q.; Wei, D.-Q. Recent Studies on Mechanisms of New Drug Candidates for Alzheimer's Disease Interacting with Amyloid- β Protofibrils Using Molecular Dynamics Simulations. In *Translational Bioinformatics and Its Application*; Wei, D.-Q., Ma, Y., Cho, W.C., Xu, Q., Zhou, F., Eds.; Springer: Dordrecht, The Netherlands, 2017; pp. 135–151.
46. Tang, M.; Wang, Z.; Zhou, Y.; Xu, W.; Li, S.; Wang, L.; Wei, D.; Qiao, Z. A Novel Drug Candidate for Alzheimer's Disease Treatment: Gx-50 Derived from *Zanthoxylum Bungeanum*. *J. Alzheimer's Dis.* **2013**, *34*, 203–213. [[CrossRef](#)]
47. Hou, S.; Gu, R.-X.; Wei, D.-Q. Inhibition of β -Amyloid Channels with a Drug Candidate wxg-50 Revealed by Molecular Dynamics Simulations. *J. Chem. Inf. Model.* **2017**, *57*, 2811–2821. [[CrossRef](#)]
48. Fan, H.-M.; Gu, R.-X.; Wang, Y.-J.; Pi, Y.-L.; Zhang, Y.-H.; Xu, Q.; Wei, D.-Q. Destabilization of Alzheimer's A β 42 Protofibrils with a Novel Drug Candidate wxg-50 by Molecular Dynamics Simulations. *J. Phys. Chem. B* **2015**, *119*, 11196–11202. [[CrossRef](#)]
49. Kanchi, P.K.; Dasmahapatra, A.K. Polyproline chains destabilize the Alzheimer's amyloid- β protofibrils: A molecular dynamics simulation study. *J. Mol. Graph. Model.* **2019**, *93*, 107456. [[CrossRef](#)]
50. Sharma, B.; Kalita, S.; Paul, A.; Mandal, B.; Paul, S. The role of caffeine as an inhibitor in the aggregation of amyloid forming peptides: A unified molecular dynamics simulation and experimental study. *RSC Adv.* **2016**, *6*, 78548–78558. [[CrossRef](#)]
51. Battisti, A.; Palumbo Piccionello, A.; Sgarbossa, A.; Vilasi, S.; Ricci, C.; Ghetti, F.; Spinozzi, F.; Marino Gammazza, A.; Giacalone, V.; Martorana, A.; et al. Curcumin-like compounds designed to modify amyloid beta peptide aggregation patterns. *RSC Adv.* **2017**, *7*, 31714–31724. [[CrossRef](#)]
52. Masuda, Y.; Fukuchi, M.; Yatagawa, T.; Tada, M.; Takeda, K.; Irie, K.; Akagi, K.; Monobe, Y.; Imazawa, T.; Takegoshi, K. Solid-state NMR analysis of interaction sites of curcumin and 42-residue amyloid β -protein fibrils. *Bioorg. Med. Chem.* **2011**, *19*, 5967–5974. [[CrossRef](#)]

53. Rao, P.P.N.; Mohamed, T.; Teckwani, K.; Tin, G. Curcumin Binding to Beta Amyloid: A Computational Study. *Chem. Biol. Drug Des.* **2015**, *86*, 813–820. [[CrossRef](#)] [[PubMed](#)]
54. Xiao, Y.; Ma, B.; McElheny, D.; Parthasarathy, S.; Long, F.; Hoshi, M.; Nussinov, R.; Ishii, Y. A β (1–42) fibril structure illuminates self-recognition and replication of amyloid in Alzheimer’s disease. *Nat. Struct. Mol. Biol.* **2015**, *22*, 499–505. [[CrossRef](#)] [[PubMed](#)]
55. Fändrich, M.; Nyström, S.; Nilsson, K.P.R.; Böckmann, A.; LeVine, H.; Hammarström, P. Amyloid fibril polymorphism: A challenge for molecular imaging and therapy. *J. Intern. Med.* **2018**, *283*, 218–237. [[CrossRef](#)] [[PubMed](#)]
56. Acosta, D.M.Á.V.; Vega, B.C.; Basurto, J.C.; Morales, L.G.F.; Rosales Hernández, M.C. Recent Advances by In Silico and In Vitro Studies of Amyloid- β 1-42 Fibril Depicted a S-Shape Conformation. *Int. J. Mol. Sci.* **2018**, *19*, 2415. [[CrossRef](#)] [[PubMed](#)]
57. Su, P.C.; Tsai, C.C.; Mehboob, S.; Hevener, K.E.; Johnson, M.E. Comparison of radii sets, entropy, QM methods, and sampling on MM-PBSA, MM-GBSA, and QM/MM-GBSA ligand binding energies of *F. tularensis* enoyl-ACP reductase (FabI). *J. Comput. Chem.* **2015**, *36*, 1859–1873. [[CrossRef](#)] [[PubMed](#)]
58. Wolber, G.; Langer, T. LigandScout: 3-D Pharmacophores Derived from Protein-Bound Ligands and Their Use as Virtual Screening Filters. *J. Chem. Inf. Model.* **2005**, *45*, 160–169. [[CrossRef](#)] [[PubMed](#)]
59. Kumar, A.; Singh, A. Ekavali A review on Alzheimer’s disease pathophysiology and its management: An update. *Pharmacol. Rep.* **2015**, *67*, 195–203. [[CrossRef](#)]
60. Auld, D.S.; Kornecook, T.J.; Bastianetto, S.; Quirion, R. Alzheimer’s disease and the basal forebrain cholinergic system: Relations to β -amyloid peptides, cognition, and treatment strategies. *Prog. Neurobiol.* **2002**, *68*, 209–245. [[CrossRef](#)]
61. Farlow, M.R.; Miller, M.L.; Pejovic, V. Treatment Options in Alzheimer’s Disease: Maximizing Benefit, Managing Expectations. *Dement. Geriatr. Cogn. Disord.* **2008**, *25*, 408–422. [[CrossRef](#)]
62. Du, W.J.; Guo, J.J.; Gao, M.T.; Hu, S.Q.; Dong, X.Y.; Han, Y.F.; Liu, F.F.; Jiang, S.; Sun, Y. Brazilin inhibits amyloid β -protein fibrillogenesis, remodels amyloid fibrils and reduces amyloid cytotoxicity. *Sci. Rep.* **2015**, *5*, 1–10. [[CrossRef](#)]
63. Tavanti, F.; Pedone, A.; Menziani, M. Computational Insight into the Effect of Natural Compounds on the Destabilization of Preformed Amyloid- β (1–40) Fibrils. *Molecules* **2018**, *23*, 1320. [[CrossRef](#)] [[PubMed](#)]
64. Pourkhodadad, S.; Alirezai, M.; Moghaddasi, M.; Ahmadvand, H.; Karami, M.; Delfan, B.; Khanipour, Z. Neuroprotective effects of oleuropein against cognitive dysfunction induced by colchicine in hippocampal CA1 area in rats. *J. Physiol. Sci.* **2016**, *66*, 397–405. [[CrossRef](#)] [[PubMed](#)]
65. Luccarini, I.; Ed Dami, T.; Grossi, C.; Rigacci, S.; Stefani, M.; Casamenti, F. Oleuropein aglycone counteracts A β 42 toxicity in the rat brain. *Neurosci. Lett.* **2014**, *558*, 67–72. [[CrossRef](#)] [[PubMed](#)]
66. Ferrándiz, M.L.; Alcaraz, M.J. Anti-inflammatory activity and inhibition of arachidonic acid metabolism by flavonoids. *Agents Actions* **1991**, *32*, 283–288. [[CrossRef](#)] [[PubMed](#)]
67. Thamizhiniyan, V.; Vijayaraghavan, K.; Subramanian, S.P. Gossypin, a flavonol glucoside protects pancreatic beta-cells from glucotoxicity in streptozotocin-induced experimental diabetes in rats. *Biomed. Prev. Nutr.* **2012**, *2*, 239–245. [[CrossRef](#)]
68. Ono, K.; Hasegawa, K.; Naiki, H.; Yamada, M. Curcumin Has Potent Anti-Amyloidogenic Effects for Alzheimer’s β -Amyloid Fibrils In Vitro. *J. Neurosci. Res.* **2004**. [[CrossRef](#)]
69. Yang, F.; Lim, G.P.; Begum, A.N.; Ubeda, O.J.; Simmons, M.R.; Ambegaokar, S.S.; Chen, P.; Kaye, R.; Glabe, C.G.; Frautschi, S.A.; et al. Curcumin inhibits formation of amyloid β oligomers and fibrils, binds plaques, and reduces amyloid in vivo. *J. Biol. Chem.* **2005**. [[CrossRef](#)]
70. Diomedea, L.; Rigacci, S.; Romeo, M.; Stefani, M.; Salmons, M. Oleuropein Aglycone Protects Transgenic *C. elegans* Strains Expressing A β 42 by Reducing Plaque Load and Motor Deficit. *PLoS ONE* **2013**, *8*, e58893. [[CrossRef](#)]
71. Rigacci, S.; Guidotti, V.; Bucciantini, M.; Nichino, D.; Relini, A.; Berti, A.; Stefani, M. A β (1-42) aggregates into non-toxic amyloid assemblies in the presence of the natural polyphenol oleuropein aglycon. *Curr. Alzheimer Res.* **2011**, *8*, 841–852. [[CrossRef](#)]
72. Pantano, D.; Luccarini, I.; Nardiello, P.; Servili, M.; Stefani, M.; Casamenti, F. Oleuropein aglycone and polyphenols from olive mill waste water ameliorate cognitive deficits and neuropathology. *Br. J. Clin. Pharmacol.* **2017**, *83*, 54–62. [[CrossRef](#)]

73. Kumar, J.; Namsechi, R.; Sim, V.L. Structure-based peptide design to modulate amyloid beta aggregation and reduce cytotoxicity. *PLoS ONE* **2015**, *10*, 1–18. [[CrossRef](#)] [[PubMed](#)]
74. Leri, M.; Natalello, A.; Bruzzone, E.; Stefani, M.; Bucciantini, M. Oleuropein aglycone and hydroxytyrosol interfere differently with toxic A β 1-42 aggregation. *Food Chem. Toxicol.* **2019**, *129*, 1–12. [[CrossRef](#)] [[PubMed](#)]
75. Lindorff-Larsen, K.; Piana, S.; Palmo, K.; Maragakis, P.; Klepeis, J.L.; Dror, R.O.; Shaw, D.E. Improved side-chain torsion potentials for the Amber ff99SB protein force field. *Proteins* **2010**, *78*, 1950–1958. [[CrossRef](#)] [[PubMed](#)]
76. Jorgensen, W.L.; Chandrasekhar, J.; Madura, J.D.; Impey, R.W.; Klein, M.L. Comparison of simple potential functions for simulating liquid water. *J. Chem. Phys.* **1983**, *79*, 926. [[CrossRef](#)]
77. Hess, B.; Hess, B.; Bekker, H.; Berendsen, H.J.C.C.; Fraaije, J.G.E.M.E.M. LINCS: A linear constraint solver for molecular simulations. *J. Comput. Chem.* **1997**, *18*, 1463–1472. [[CrossRef](#)]
78. Bussi, G.; Donadio, D.; Parrinello, M. Canonical sampling through velocity rescaling. *J. Chem. Phys.* **2007**, *126*, 14101. [[CrossRef](#)]
79. Berendsen, H.J.C.J.C.; Postma, J.P.M.; Van Gunsteren, W.F.; DiNola, A.; Haak, J.R. Molecular dynamics with coupling to an external bath. *J. Chem. Phys.* **1984**, *81*, 3684–3690. [[CrossRef](#)]
80. Parrinello, M.; Rahman, A. Polymorphic transitions in single crystals: A new molecular dynamics method. *J. Appl. Phys.* **1981**, *52*, 7182–7190. [[CrossRef](#)]
81. Darden, T.; York, D.; Pedersen, L. Particle mesh Ewald: An N-log(N) method for Ewald sums in large systems. *J. Chem. Phys.* **1993**, *98*, 10089. [[CrossRef](#)]
82. Abraham, M.J.; Murtola, T.; Schulz, R.; Páll, S.; Smith, J.C.; Hess, B.; Lindahl, E. GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. *SoftwareX* **2015**, *1–2*, 19–25. [[CrossRef](#)]
83. Humphrey, W.; Dalke, A.; Schulten, K. VMD: Visual molecular dynamics. *J. Mol. Graph.* **1996**, *14*, 27–28, 33–38. [[CrossRef](#)]
84. Grasso, G.; Muscat, S.; Rebella, M.; Morbiducci, U.; Audenino, A.; Danani, A.; Deriu, M.A. Cell penetrating peptide modulation of membrane biomechanics by Molecular dynamics. *J. Biomech.* **2018**, *73*, 137–144. [[CrossRef](#)] [[PubMed](#)]
85. Kim, S.; Chen, J.; Cheng, T.; Gindulyte, A.; He, J.; He, S.; Li, Q.; Shoemaker, B.A.; Thiessen, P.A.; Yu, B.; et al. PubChem 2019 update: Improved access to chemical data. *Nucleic Acids Res.* **2019**, *47*, D1102–D1109. [[CrossRef](#)] [[PubMed](#)]
86. Wang, J.; Wolf, R.M.; Caldwell, J.W.; Kollman, P.A.; Case, D.A. Development and testing of a general amber force field. *J. Comput. Chem.* **2004**, *25*, 1157–1174. [[CrossRef](#)]
87. Wang, J.; Wang, W.; Kollman, P.A.; Case, D.A. Automatic atom type and bond type perception in molecular mechanical calculations. *J. Mol. Graph. Model.* **2006**, *25*, 247–260. [[CrossRef](#)]
88. Jakalian, A.; Jack, D.B.; Bayly, C.I. Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation. *J. Comput. Chem.* **2002**, *23*, 1623–1641. [[CrossRef](#)]
89. Klejborowska, G.; Urbaniak, A.; Preto, J.; Maj, E.; Moshari, M.; Wietrzyk, J.; Tuszyński, J.A.; Chambers, T.C.; Huczynski, A. Synthesis, biological evaluation and molecular docking studies of new amides of 4-bromothiocolchicine as anticancer agents. *Bioorg. Med. Chem.* **2019**, *76*, 115144. [[CrossRef](#)]
90. Sahakyan, H.; Abelyan, N.; Arakelov, V.; Arakelov, G.; Nazaryan, K. In silico study of colchicine resistance molecular mechanisms caused by tubulin structural polymorphism. *PLoS ONE* **2019**, *14*, e0221532. [[CrossRef](#)]
91. Kumbhar, B.V.; Borogaon, A.; Panda, D.; Kunwar, A. Exploring the Origin of Differential Binding Affinities of Human Tubulin Isoforms $\alpha\beta$ II, $\alpha\beta$ III and $\alpha\beta$ IV for DAMA-Colchicine Using Homology Modelling, Molecular Docking and Molecular Dynamics Simulations. *PLoS ONE* **2016**, *11*, e0156048. [[CrossRef](#)]
92. Gajewski, M.M.; Tuszyński, J.A.; Barakat, K.; Huzil, J.T.; Klobukowski, M. Interactions of laulimalide, peloruside, and their derivatives with the isoforms of β -tubulin. *Can. J. Chem.* **2013**, *91*, 511–517. [[CrossRef](#)]
93. Morris, G.M.; Huey, R.; Lindstrom, W.; Sanner, M.F.; Belew, R.K.;Goodsell, D.S.; Olson, A.J. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. *J. Comput. Chem.* **2009**, *30*, 2785–2791. [[CrossRef](#)]
94. Genheden, S.; Ryde, U. The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. *Expert Opin. Drug Discov.* **2015**, *10*, 449–461. [[CrossRef](#)]

95. Sun, H.; Duan, L.; Chen, F.; Liu, H.; Wang, Z.; Pan, P.; Zhu, F.; Zhang, J.Z.H.; Hou, T. Assessing the performance of MM/PBSA and MM/GBSA methods. 7. Entropy effects on the performance of end-point binding free energy calculation approaches. *Phys. Chem. Chem. Phys.* **2018**, *20*, 14450–14460. [[CrossRef](#)]
96. Hou, T.; Wang, J.; Li, Y.; Wang, W. Assessing the performance of the molecular mechanics/Poisson Boltzmann surface area and molecular mechanics/generalized Born surface area methods. II. The accuracy of ranking poses generated from docking. *J. Comput. Chem.* **2011**, *32*, 866–877. [[CrossRef](#)]
97. Grasso, G.; Leanza, L.; Morbiducci, U.; Danani, A.; Deriu, M.A. Aminoacid Substitutions in the Glycine Zipper Affect the Conformational Stability of Amyloid Beta Fibrils. *J. Biomol. Struct. Dyn.* **2019**, 1–13. [[CrossRef](#)]



© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).